Alzheimer's disease
Alzheimer's disease
复制标题
DOI：
10.1016/s0140-6736(10)61349-9
复制
发表时间：
2011-03-19
期刊：
影响因子：
168.9
通讯作者：
Jones, Emma
中科院分区：
文献类型：
--
作者：
Ballard, Clive;Gauthier, Serge;Jones, Emma
据估计，全球有2400万人患有痴呆症，其中大多数人被认为患有阿尔茨海默氏症。因此，阿尔茨海默病是一个重大的公共卫生问题，已被确定为研究重点。尽管有获得许可的治疗方法可以缓解阿尔茨海默病的症状，但迫切需要提高我们对发病机制的理解，以使疾病修改治疗的开发成为可能。改善诊断的方法也在向前发展，但需要更好的共识来开发一组支持临床诊断的生物神经成像生物标记物。现在有强有力的证据表明阿尔茨海默病、痴呆症和认知能力下降的潜在风险和保护因素，但需要进一步的工作来更好地了解这些因素，并确定干预措施是否可以大幅降低这些风险。在本次研讨会中，我们提供了关于阿尔茨海默病的流行病学、发病机制、诊断和治疗的最新证据的概述，并讨论了降低疾病发展风险的潜在方法。
An estimated 24 million people worldwide have dementia, the majority of whom are thought to have Alzheimer's disease. Thus, Alzheimer's disease represents a major public health concern and has been identified as a research priority. Although there are licensed treatments that can alleviate symptoms of Alzheimer's disease, there is a pressing need to improve our understanding of pathogenesis to enable development of disease-modifying treatments. Methods for improving diagnosis are also moving forward, but a better consensus is needed for development of a panel of biological aneuroimaging biomarkers that support clinical diagnosis. There is now strong evidence of potential risk and protective factors for Alzheimer's disease, dementia, and cognitive decline, but further work is needed to understand these better and to establish whether interventions can substantially lower these risks. In this Seminar, we provide an overview of recent evidence regarding the epidemiology, pathogenesis, diagnosis, and treatment of Alzheimer's disease, and discuss potential ways to reduce the risk of developing the disease.